Kura Oncology Inc KURA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
20.71UNCH (UNCH)
Volume
16,663
Close
20.71quote price arrow down-0.06 (-0.29%)
Volume
556,812
52 week range
7.41 - 24.17
Loading...
  • Open20.95
  • Day High21.03
  • Day Low20.02
  • Prev Close20.77
  • 52 Week High24.17
  • 52 Week High Date03/11/24
  • 52 Week Low7.41
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap1.578B
  • Shares Out76.18M
  • 10 Day Average Volume0.60M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change44.02

KEY STATS

  • Open20.95
  • Day High21.03
  • Day Low20.02
  • Prev Close20.77
  • 52 Week High24.17
  • 52 Week High Date03/11/24
  • 52 Week Low7.41
  • 52 Week Low Date10/25/23
  • Market Cap1.578B
  • Shares Out76.18M
  • 10 Day Average Volume0.60M
  • Dividend-
  • Dividend Yield-
  • Beta0.94
  • YTD % Change44.02

RATIOS/PROFITABILITY

  • EPS (TTM)-2.18
  • P/E (TTM)-9.52
  • Fwd P/E (NTM)-8.25
  • EBITDA (TTM)-182.813M
  • ROE (TTM)-37.34%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)1.86%

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Kura Oncology Inc

 

Profile

MORE
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine...
Troy Wilson J.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Kathleen Ford
Chief Operating Officer
Address
12730 HIGH BLUFF DRIVE, SUITE 400
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
SLNO
Soleno Therapeutics Inc
44.99-2.65-5.56%
MORF
Morphic Holding Inc
28.62-0.51-1.75%
AKRO
Akero Therapeutics Inc
19.65-1.15-5.53%
INBX
Inhibrx Inc
34.29-0.40-1.15%
EWTX
Edgewise Therapeutics Inc
18.33-1.67-8.35%